The primary outcome occurred in 394 patients ( 27.5 % ) in the benznidazole group and in 414 ( 29.1 % ) in the placebo group ( hazard ratio , 0.93 ; 95 % confidence interval [ CI ] , 0.81 to 1.07 ; P = 0.31 ) .